The 5% decrease in full-year 2017 sales might have disappointed AstraZeneca investors, but China remained a bright spot. The British pharma is now stepping up its game there through two new deals with Chinese internet giants Alibaba and Tencent.Original Article
AstraZeneca allies with Alibaba and Tencent as its China sales soar
